ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Fisetin attenuates glutamate-induced excitotoxicity and modulates neural progenitor cell dynamics in vitro.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases (NDs) are characterized by progressive neuronal loss associated with excitotoxicity, oxidative stress, neuroinflammation, and impaired neuroplasticity. Fisetin, a naturally occurring flavonoid, has emerged as a potential neuroprotective compound due to its antioxidant and anti-inflammatory properties. In this study, we investigated the effects of fisetin in cellular models of glutamate-induced excitotoxicity and neural progenitor differentiation. Differentiated PC-12 cells were exposed to 13 mM glutamate and treated with fisetin. Cell viability was assessed using the MTT assay, reactive oxygen species (ROS) production by dihydroethidium assay, and TNF-α levels by ELISA. In parallel, subventricular zone (SVZ)-derived neurosphere cultures were used to evaluate proliferation and differentiation. Fisetin significantly attenuated glutamate-induced cytotoxicity, reduced ROS production, and decreased TNF-α levels. In neurosphere cultures, fisetin reduced neurosphere size without altering neurosphere number, suggesting modulation of progenitor cell dynamics without affecting neural stem cell self-renewal. Moreover, fisetin increased β-III-tubulin-positive neuroblasts without affecting GFAP-positive glial cells. These findings support the pharmacological potential of fisetin in modulating key pathological features of NDs and encourage further in vivo validation and molecular pathway analysis.
Indexed as
Identifiers
42472719What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.